Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Novo Nordisk Partners with OpenAI to Accelerate Drug Discovery and Transform Healthcare Operations

Fineline Cube Apr 15, 2026
Company Deals

AC Immune and Eli Lilly Amend 2018 Alzheimer’s Partnership to Advance Tau Morphomer Candidates

Fineline Cube Apr 15, 2026
Company Deals

Autobio Diagnostics Expands Global IVD Footprint with Dual Vietnam Partnerships

Fineline Cube Apr 15, 2026
Company Deals

Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma

Fineline Cube Apr 15, 2026
Company Deals

UCB Secures EU Approval for Kygevvi as First-Ever Treatment for Ultra-Rare TK2 Deficiency

Fineline Cube Apr 15, 2026
Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Fineline Cube Apr 15, 2026
Company Drug

Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders

Fineline Cube Apr 15, 2026
Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in Phase III Trial for Novel Long-Acting Insulin GZR33 in Type 2 Diabetes

Fineline Cube Apr 15, 2026
Company Drug

AstraZeneca’s Fasenra Approved by EU for Eosinophilic Granulomatosis Treatment

Fineline Cube Oct 29, 2024

UK pharmaceutical giant AstraZeneca Inc. (NASDAQ: AZN) has received marketing approval from the European Commission...

Company Drug

AbbVie Inks $1.4 Billion Deal to Acquire Alzheimer’s Drug Developer Aliada Therapeutics

Fineline Cube Oct 29, 2024

US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a definitive agreement to acquire all...

Company Drug

CSPC Pharmaceutical’s SYS6020 Receives NMPA Approval for Myasthenia Gravis Clinical Trial

Fineline Cube Oct 28, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Eli Lilly’s Ebglyss Shows Positive Results in Phase III Study for Atopic Dermatitis Patients Previously Treated with Dupilumab

Fineline Cube Oct 28, 2024

Eli Lilly & Co. (NYSE: LLY), a leading U.S. pharmaceutical company, has announced the results...

Company

CANbridge Pharmaceuticals Scales Back US Operations, Focuses on China for R&D and Commercialization

Fineline Cube Oct 28, 2024

CANbridge Pharmaceuticals Inc., (HKG: 1228), a China-based pharmaceutical company specializing in rare diseases, has announced...

Company Drug

Biogen’s Felzartamab Demonstrates Promising Results in Phase II Study for IgA Nephropathy

Fineline Cube Oct 28, 2024

Biogen Inc. (NASDAQ: BIIB), a prominent biopharmaceutical company based in the U.S., has announced comprehensive...

Company Drug

Humanwell Healthcare Receives NMPA Approval for Chemically Synthesized Semaglutide Clinical Trial

Fineline Cube Oct 28, 2024

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079), a leading healthcare company based in China, has...

Company Drug

RiboX Therapeutics’ Circular RNA Therapy RXRG001 Gets FDA Green Light for Dry Mouth Clinical Trial

Fineline Cube Oct 28, 2024

RiboX Therapeutics, a Shanghai-based developer of circular RNA (circRNA) therapies, has announced that it has...

Company Drug

AstraZeneca’s Zoladex Receives NMPA Approval for Higher Dosage Form in Breast Cancer Treatment

Fineline Cube Oct 28, 2024

AstraZeneca Inc., (AZ, NASDAQ: AZN), a UK-based pharmaceutical giant, has announced that it has received...

Company Drug

MicuRx Pharmaceuticals’ Antibiotic MRX-5 Completes Successful Phase I Clinical Trial in Australia

Fineline Cube Oct 28, 2024

MicuRx Pharmaceuticals Inc. (SHA: 688373), a Sino-US pharmaceutical company, has announced the successful completion of...

Policy / Regulatory

NMPA’s CDE Prioritizes Marketing Filings for Innovative Drugs with Priority Review Status

Fineline Cube Oct 28, 2024

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) released a...

Company Medical Device

Wantai Biological’s P85 Ab Detection Kit Receives NMPA Approval for Nasopharyngeal Carcinoma Screening

Fineline Cube Oct 28, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a Chinese pharmaceutical company, announced last...

Company Drug

Chinese ADCs from Escugen, Hansoh, and MediLink Therapeutics Eye Breakthrough Designations in China

Fineline Cube Oct 28, 2024

The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has indicated on...

Company Deals

GSK Commits USD 800 Million to New State-of-the-Art Manufacturing Facility in Pennsylvania

Fineline Cube Oct 28, 2024

GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced a significant investment in...

Company Deals

ImmuneOnco Biopharmaceuticals Partners with Yangtze River Pharmaceutical to Boost Pipeline Development

Fineline Cube Oct 28, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a biopharmaceutical company based in China, has entered...

Company Deals Drug

LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS

Fineline Cube Oct 28, 2024

LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control...

Company Drug

Zhuhai Beihai Biotech’s Beizary Receives FDA Clearance for Multiple Cancer Indications

Fineline Cube Oct 28, 2024

Zhuhai Beihai Biotech Co., Ltd has announced that it has received marketing clearance from the...

Company Drug

BeiGene’s PD-1 Inhibitor Tevimbra Scores First US Prescription, Offers More Affordable Option

Fineline Cube Oct 28, 2024

BeiGene Ltd, a leading China-based biotechnology company (NASDAQ: BGNE; HKG: 6160; SHA: 688235), has announced...

Company Drug

RemeGen’s Telitacicept Receives Priority Review Status from China’s CDE for gMG Treatment

Fineline Cube Oct 28, 2024

RemeGen (HKG: 9995), a China-based pharmaceutical company, has announced that the Center for Drug Evaluation...

Policy / Regulatory

China’s Pharmaceutical Trade Reaches USD 147.491 Billion in First Three Quarters, Export Growth Outpaces Imports

Fineline Cube Oct 28, 2024

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Posts pagination

1 … 263 264 265 … 651

Recent updates

  • Novo Nordisk Partners with OpenAI to Accelerate Drug Discovery and Transform Healthcare Operations
  • Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders
  • China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives
  • Gan & Lee Pharmaceuticals Doses First Patient in Phase III Trial for Novel Long-Acting Insulin GZR33 in Type 2 Diabetes
  • AC Immune and Eli Lilly Amend 2018 Alzheimer’s Partnership to Advance Tau Morphomer Candidates
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Novo Nordisk Partners with OpenAI to Accelerate Drug Discovery and Transform Healthcare Operations

Company Drug

Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders

Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in Phase III Trial for Novel Long-Acting Insulin GZR33 in Type 2 Diabetes

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.